Skip to main navigation Skip to search Skip to main content

A Phase 3, Twelve-week, Multi-Center, Multinational, Randomized, Double-Blind, Double-Dummy, Parallel Group Study to Determine the Efficacy, Safety and Tolerability of P2B001 Compared to its Individual Components in Subjects With Early Park

University at Buffalo

Project: Research

Project Details

StatusFinished
Effective start/end date06/4/18 → 11/4/22

Funding

  • Pharmaceutical Research Associates Incorporated: $105,483.00